Cytokinetics
CYTK
132 hedge funds and large institutions have $575M invested in Cytokinetics in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 39 reducing their positions, and 20 closing their positions.
42% more call options, than puts
Call options by funds: $9.37M | Put options by funds: $6.62M
36% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 39
24% more capital invested
Capital invested by funds: $465M → $575M (+$111M)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
3% less funds holding
Funds holding: 136 → 132 (-4)
4.93% less ownership
Funds ownership: 78.84% → 73.92% (-4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15.7M |
| 2 |
PA
Pinnacle Associates
New York
|
+$13.8M |
| 3 |
BlackRock
New York
|
+$8.16M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.81M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$10.2M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.02M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$4.96M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.3M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$3.93M |
CYTK Hedge Fund Activity: Q3 2017 in Review
132 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2017, worth a combined $575M — up 24% from $465M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CYTK and 19 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 53 added.
The largest buyer was Citadel Advisors, adding an estimated $15.7M. The largest seller was BVF Inc, cutting an estimated $10.2M.
- 132 institutional investors held Cytokinetics (CYTK) as of Q3 2017, down from 136 in Q2 2017.
- Funds reported $575M of Cytokinetics stock for Q3 2017, up 24% quarter-over-quarter.
- 19 funds opened new Cytokinetics positions in Q3 2017 and 20 closed out, a net change of -1 holder.
- The largest Cytokinetics buyer in Q3 2017 was Citadel Advisors, an estimated $15.7M added.
- The largest Cytokinetics seller in Q3 2017 was BVF Inc, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2017.